These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9166459)

  • 1. Using clinical trial information in the practice of medicine.
    Henderson IC
    Cancer J Sci Am; 1995; 1(2):101-3. PubMed ID: 9166459
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant-preoperative-chemotherapy for breast cancer--preliminary report of the Vancouver trial.
    Ragaz J; Baird R; Rebbeck P; Coldman A; Goldie J
    Prog Clin Biol Res; 1985; 201():77-87. PubMed ID: 3912768
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
    Samur M; Bozcuk HS
    J Clin Oncol; 2003 Jun; 21(12):2444; author reply 2445-7. PubMed ID: 12805349
    [No Abstract]   [Full Text] [Related]  

  • 5. Breast cancer 1984: state of the art.
    Sledge GW
    Indiana Med; 1984 Dec; 77(12):935-9. PubMed ID: 6394645
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.
    Albain KS
    J Natl Cancer Inst; 2004 Dec; 96(24):1801-4. PubMed ID: 15601631
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 8. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
    Lyman GH; Dale DC; Crawford J
    J Clin Oncol; 2003 Dec; 21(24):4524-31. PubMed ID: 14673039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible ovarian ablation or chemotherapy: are we ready for quality of life to guide adjuvant treatment decisions in breast cancer?
    Goodwin PJ
    J Clin Oncol; 2003 Dec; 21(24):4474-5. PubMed ID: 14610047
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy.
    Joly F; Espié M; Marty M; Héron JF; Henry-Amar M
    Br J Cancer; 2000 Sep; 83(5):577-82. PubMed ID: 10944595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crossing the quality chasm in breast cancer care.
    Silliman RA
    J Clin Oncol; 2004 Sep; 22(18):3654-6. PubMed ID: 15289489
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial.
    Bellon JR; Come SE; Gelman RS; Henderson IC; Shulman LN; Silver BJ; Harris JR; Recht A
    J Clin Oncol; 2005 Mar; 23(9):1934-40. PubMed ID: 15774786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy with four drugs for stage 2 breast cancer.
    Wheeler TK; Edelstyn GA; Bates TS; Brinkley D; Evans RG; Kitchen G; MacRae KD; Nicol NT; Spittle M; Wheeler TK
    Eur J Cancer (1965); 1980; Suppl 1():161-3. PubMed ID: 7032926
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.